PTGX analyst estimates
Protagonist Therapeutics (PTGX) analyst ratings, the average price target and its range, and every firm's latest call.
PTGX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 12, 2026 | UBS | UBS Starts Protagonist Therapeutics (PTGX) at Buy | $184.00 |
| Sep 1, 2026 | Barclays | Protagonist Therapeutics price target raised to $180 from $153 at Barclays | $180.00 |
| Sep 1, 2026 | BMO Capital | Protagonist Therapeutics price target raised to $190 from $178 at BMO Capital | $190.00 |
| Aug 31, 2026 | H.C. Wainwright | Protagonist Therapeutics price target raised to $170 from $167 at H.C. Wainwright | $170.00 |
| Aug 17, 2026 | BMO Capital | Protagonist Therapeutics price target raised to $178 from $112 at BMO Capital | $178.00 |
| Aug 10, 2026 | Goldman Sachs | Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy | $186.00 |
| Aug 10, 2026 | Wedbush | Protagonist Therapeutics price target raised to $173 from $118 at Wedbush | $173.00 |
| Aug 10, 2026 | Truist Financial | Protagonist Therapeutics price target raised to $170 from $145 at Truist | $170.00 |
| Aug 6, 2026 | Barclays | Protagonist Therapeutics price target raised to $153 from $151 at Barclays | $153.00 |
| Jul 17, 2026 | Johnson Rice | Protagonist Therapeutics price target raised to $165 from $137 at Citizens | $165.00 |
| Jul 14, 2026 | Barclays | Protagonist Therapeutics price target raised to $151 from $119 at Barclays | $151.00 |
| Jul 7, 2026 | Truist Financial | Protagonist Therapeutics (PTGX) PT Raised to $145 at Truist SecuritiesMember Login | $145.00 |
| May 6, 2026 | Goldman Sachs | Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs | $110.00 |
| Apr 14, 2026 | Truist Financial | Protagonist Therapeutics price target raised to $121 from $110 at Truist | $121.00 |
| Mar 18, 2026 | Jefferies | Protagonist Therapeutics (PTGX) PT Raised to $121 at Jefferies | $121.00 |
- 14 firms rate PTGX: 14 buy, 0 hold, 0 sell.
- The average price target is $177.25 from 8 analysts, from $165.00 to $190.00.
Updated 2026-11-03 00:02 UTC